Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene [Yahoo! Finance]
CG Oncology, Inc. - Common stock (CGON)
Company Research
Source: Yahoo! Finance
coverage of CG Oncology with a Buy rating and $90 price target. The firm believes that the non-muscle invasive bladder cancer market has lots of patients and pricing power. Guggenheim also highlighted CG Oncology's cretostimogene, which will enter FDA review in 2026. It was in its Q2 2025 earnings update that the company reported that it is developing cretostimogene grenadenorepvec, which is an investigational oncolytic immunotherapy, as a potential bladder-sparing therapeutic for NMIBC. Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene CG Oncology also initiated the CORE-008 Cohort CX trial, which is evaluating the combination of cretostimogene and gemcitabine in high-risk NMIBC patients. Upcoming milestones include the completion of Phase 3 enrollment for the PIVOT-006 trial in Q3 and the initiation of a BLA submission for cretostimogene in Q4. CG Oncology Inc. (NASDAQ:CGON) is a late-stage clinical biopharmace
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CGON
News
- New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder CancerGlobeNewswire
- CG Oncology Announces New Board Member and Board Transition [Yahoo! Finance]Yahoo! Finance
- CG Oncology Announces New Board Member and Board TransitionGlobeNewswire
- CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting [Yahoo! Finance]Yahoo! Finance
- CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual MeetingGlobeNewswire
CGON
Earnings
- 11/14/25 - In-Line
CGON
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 3
- 11/26/25 - Form 8-K
- CGON's page on the SEC website